Contents

Current Pharmaceutical Design, Volume 18 - Number 5

Editorial [Hot Topic: New Developments in Pharmaceutical Treatments for Cystic Fibrosis (Executive Guest Editor: Hartmut Grasemann)]

, 18(5): 613

Hartmut Grasemann


DOI: 10.2174/138161212799315966




New Therapies in Cystic Fibrosis

, 18(5): 614 - 627

Felix Ratjen and Hartmut Grasemann


DOI: 10.2174/138161212799315984




Identification and Validation of Hits from High Throughput Screens for CFTR Modulators

, 18(5): 628 - 641

Stan Pasyk, Steven Molinski, Wilson Yu, Paul D.W. Eckford and Christine E. Bear


DOI: 10.2174/138161212799315957




Progress in Gene and Cell Therapy for Cystic Fibrosis Lung Disease

, 18(5): 642 - 662

Uta Griesenbach and Eric W.F.W. Alton


DOI: 10.2174/138161212799315993




Early In Vivo Testing to Assess New Therapeutic Interventions in CF Patients

, 18(5): 663 - 673

Tanja Gonska


DOI: 10.2174/138161212799315948




Modifier Gene Studies to Identify New Therapeutic Targets in Cystic Fibrosis

, 18(5): 674 - 682

Ruslan Dorfman


DOI: 10.2174/138161212799315920




New Developments in Inhaled Antibiotics for the Treatment of Pseudomonas aeruginosa

, 18(5): 683 - 695

Thomas Hofmann


DOI: 10.2174/138161212799315975




New Treatments for Emerging Cystic Fibrosis Pathogens other than Pseudomonas

, 18(5): 696 - 725

Valerie Waters


DOI: 10.2174/138161212799315939




Nitric Oxide and L-Arginine Deficiency in Cystic Fibrosis

, 18(5): 726 - 736

Hartmut Grasemann and Felix Ratjen


DOI: 10.2174/138161212799315911




New Developments In Treatment After Lung Transplantation

, 18(5): 737 - 746

Christian Benden, Lara Danziger-Isakov and Albert Faro


DOI: 10.2174/138161212799315902




Webmaster Contact: info@benthamscience.org
Copyright © 2018 Bentham Science